一家三级医院对 COVID-19 后人群中粘孢子菌病患者特征和治疗方法的回顾性研究。

IF 1.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Jada Naga Lakshmi, Jada Bala Sai Kalyan, Tanniru Govardhana Priya, Tummala Sushma, Gaddam Rukmini, R V L S Mounica, Tinnaluri Vishnu Vardhan
{"title":"一家三级医院对 COVID-19 后人群中粘孢子菌病患者特征和治疗方法的回顾性研究。","authors":"Jada Naga Lakshmi, Jada Bala Sai Kalyan, Tanniru Govardhana Priya, Tummala Sushma, Gaddam Rukmini, R V L S Mounica, Tinnaluri Vishnu Vardhan","doi":"10.1136/ejhpharm-2024-004127","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Along with the COVID-19 pandemic, another illness wreaking havoc in India is mucormycosis, also known as black fungus. Mucormycosis was previously known as zygomycotic infection, which is a consequential type of infection caused by several mildews known as Mucoromycetes. It is an invasive type of disease which occurs more commonly in individuals with low and weakened immunity. The main objective of this study was to identify the mucormycosis cases post COVID-19 and to determine the risk factors and treatment for positive cases.</p><p><strong>Methods: </strong>Thirty-three patients (61% men, 39% women; mean age 55 years) with mucormycosis were identified in the Department of Oral and Maxillofacial Surgery.</p><p><strong>Results: </strong>People who received COVID-19 vaccines had a lower rate of infection with the fungus than non-vaccinated people. In steroid users the risk was very high compared with those not taking steroids.</p><p><strong>Conclusion: </strong>The majority of non vaccinated patients with preexisting co-morbidity conditions like diabetes, chronic illnesses and irregular use of steroids during COVID-19, might have greater risks of getting mucormycosis rather than normal COVID-19 positive cases.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Retrospective study of patient characteristics and treatment for mucormycosis in post COVID-19 population in a tertiary care hospital.\",\"authors\":\"Jada Naga Lakshmi, Jada Bala Sai Kalyan, Tanniru Govardhana Priya, Tummala Sushma, Gaddam Rukmini, R V L S Mounica, Tinnaluri Vishnu Vardhan\",\"doi\":\"10.1136/ejhpharm-2024-004127\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Along with the COVID-19 pandemic, another illness wreaking havoc in India is mucormycosis, also known as black fungus. Mucormycosis was previously known as zygomycotic infection, which is a consequential type of infection caused by several mildews known as Mucoromycetes. It is an invasive type of disease which occurs more commonly in individuals with low and weakened immunity. The main objective of this study was to identify the mucormycosis cases post COVID-19 and to determine the risk factors and treatment for positive cases.</p><p><strong>Methods: </strong>Thirty-three patients (61% men, 39% women; mean age 55 years) with mucormycosis were identified in the Department of Oral and Maxillofacial Surgery.</p><p><strong>Results: </strong>People who received COVID-19 vaccines had a lower rate of infection with the fungus than non-vaccinated people. In steroid users the risk was very high compared with those not taking steroids.</p><p><strong>Conclusion: </strong>The majority of non vaccinated patients with preexisting co-morbidity conditions like diabetes, chronic illnesses and irregular use of steroids during COVID-19, might have greater risks of getting mucormycosis rather than normal COVID-19 positive cases.</p>\",\"PeriodicalId\":12050,\"journal\":{\"name\":\"European journal of hospital pharmacy : science and practice\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-06-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European journal of hospital pharmacy : science and practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1136/ejhpharm-2024-004127\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of hospital pharmacy : science and practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/ejhpharm-2024-004127","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

目的:除 COVID-19 大流行病外,另一种在印度造成严重破坏的疾病是粘孢子菌病,又称黑木耳。粘孢子菌病以前被称为子囊菌感染,是由几种称为粘孢子菌的霉菌引起的一种继发性感染。它是一种侵袭性疾病,通常发生在免疫力低下的人身上。本研究的主要目的是确定 COVID-19 后的粘孢子菌病病例,并确定阳性病例的风险因素和治疗方法:方法:口腔颌面外科共发现 33 例粘孢子菌病患者(61% 为男性,39% 为女性;平均年龄 55 岁):结果:接种过 COVID-19 疫苗的人感染粘孢子菌的比例低于未接种疫苗的人。与未服用类固醇的人相比,服用类固醇的人感染真菌的风险非常高:结论:与 COVID-19 阳性病例相比,大多数未接种疫苗的患者在接种 COVID-19 疫苗前已患有糖尿病、慢性疾病等并发症,且在接种期间不规则使用类固醇,因此他们感染粘孢子菌病的风险可能更高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Retrospective study of patient characteristics and treatment for mucormycosis in post COVID-19 population in a tertiary care hospital.

Objectives: Along with the COVID-19 pandemic, another illness wreaking havoc in India is mucormycosis, also known as black fungus. Mucormycosis was previously known as zygomycotic infection, which is a consequential type of infection caused by several mildews known as Mucoromycetes. It is an invasive type of disease which occurs more commonly in individuals with low and weakened immunity. The main objective of this study was to identify the mucormycosis cases post COVID-19 and to determine the risk factors and treatment for positive cases.

Methods: Thirty-three patients (61% men, 39% women; mean age 55 years) with mucormycosis were identified in the Department of Oral and Maxillofacial Surgery.

Results: People who received COVID-19 vaccines had a lower rate of infection with the fungus than non-vaccinated people. In steroid users the risk was very high compared with those not taking steroids.

Conclusion: The majority of non vaccinated patients with preexisting co-morbidity conditions like diabetes, chronic illnesses and irregular use of steroids during COVID-19, might have greater risks of getting mucormycosis rather than normal COVID-19 positive cases.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.40
自引率
5.90%
发文量
104
审稿时长
6-12 weeks
期刊介绍: European Journal of Hospital Pharmacy (EJHP) offers a high quality, peer-reviewed platform for the publication of practical and innovative research which aims to strengthen the profile and professional status of hospital pharmacists. EJHP is committed to being the leading journal on all aspects of hospital pharmacy, thereby advancing the science, practice and profession of hospital pharmacy. The journal aims to become a major source for education and inspiration to improve practice and the standard of patient care in hospitals and related institutions worldwide. EJHP is the only official journal of the European Association of Hospital Pharmacists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信